A Treatment for Sleeping Sickness
Infectious Diseases Summary and Comment
Subscription required
In a study conducted in Sudan, eflornithine was effective and relatively safe for treating African sleeping sickness.
CNS Relapse in Non-Hodgkin Lymphoma
Oncology and Hematology Summary and Comment
Subscription required
Patients with B-cell NHL who present with two or more extranodal sites of involvement, elevated LDH levels, and high IPI scores have high risk for CNS relapse.
Persistence of Neuropsychologic Impairment After Starting ART
HIV/AIDS Summary and Comment
Free
More than 60% of patients with HIV-related neurocognitive impairment at baseline continued to have persistent neuropsychologic deficits while receiving ART. Baseline severity of impairment was identified as the major determinant.
By Keith Henry, MD
June 25, 2007
Covering:
Tozzi V et al., J Acquir Immune Defic Syndr 2007 Jun 1; 45:174-82
Neurotoxicity Following Intrathecal Chemotherapy
Oncology and Hematology Summary and Comment
Free
In a phase II study, intrathecal liposomal cytarabine was associated with unexpected neurotoxicity in some ALL patients who received concomitant high-dose intravenous methotrexate and cytarabine.
By Michael E. Williams, MD
April 30, 2007
Covering:
Jabbour E et al., Blood 2007 Apr 15; 109:3214-8
Delirium After Hematopoietic Stem-Cell Transplantation Affects HRQOL
Oncology and Hematology Summary and Comment
Free
In a stem-cell transplant population, delirium was associated with adverse effects on neurocognition and with high levels of distress at 80 days post-transplant.
By Barbara A. Murphy, MD
April 13, 2007
Covering:
Fann JR et al., J Clin Oncol 2007 Apr 1; 25:1223-31
The Spectrum of Herpes Simplex Encephalitis in Children
Infectious Diseases Summary and Comment
Registration required
In 25% of children with herpes simplex encephalitis, CSF PCR results were negative; in another 13%, a positive PCR test followed a negative one.
By Robert S. Baltimore, MD
February 21, 2007
Covering:
Elbers JM et al., Pediatrics 2007 Feb; 119:e399-407
Zostavax: A New Vaccine to Reduce the Risk for Herpes Zoster in Older Adults
Infectious Diseases Vaccine Watch
Free
Results from a large study show this new vaccine to be very effective, particularly in 60- to 69-year-olds.
By Stephen G. Baum, MD
June 22, 2006
